Biofrontera AG
B8FK
Company Profile
Business description
Biofrontera AG is active in the field of healthcare. It manufactures pharmaceutical products, especially medical cosmetics and dermatological drugs for the care and treatment of skin diseases. Its suite of products includes the prescription drugs Ameluz and BF-RhodoLED, for the treatment of actinic keratosis and Belixos, for the regenerative care of reddened and inflamed skin.
Contact
Hemmelrather Weg 201
LeverkusenNW51377
DEUT: +49 214876320
Sector
Healthcare
Stock type
Defensive
Industry
Drug Manufacturers - Specialty & Generic
Fiscal Year End
31 December 2025
Employees
87
Stocks News & Analysis
stocks
10 best US growth stocks to buy for the long term
The stocks of these high-quality growth companies look undervalued today.
stocks
Higher fair value for overvalued ASX tech share
Underlying secular growth stronger than we thought.
stocks
Nvidia: Collaboration with Intel might bring some goodwill with the US
We doubt the $5 billion is meaningful enough to force Nvidia to use Intel, either for core products or even for the chips in collaboration.
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 9,102.10 | 11.70 | 0.13% |
| CAC 40 | 7,805.86 | 47.73 | -0.61% |
| DAX 40 | 23,469.95 | 169.46 | -0.72% |
| Dow JONES (US) | 46,224.48 | 90.79 | -0.20% |
| FTSE 100 | 9,214.98 | 1.69 | -0.02% |
| HKSE | 26,344.14 | 200.96 | -0.76% |
| NASDAQ | 22,678.43 | 46.95 | 0.21% |
| Nikkei 225 | 45,493.66 | 447.85 | 0.99% |
| NZX 50 Index | 13,141.54 | 90.12 | -0.68% |
| S&P 500 | 6,667.31 | 2.95 | 0.04% |
| S&P/ASX 200 | 8,810.90 | 11.40 | 0.13% |
| SSE Composite Index | 3,828.58 | 8.49 | 0.22% |